The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform

Guowang Xu - One of the best experts on this subject based on the ideXlab platform.

  • metabolomic identification of potential phospholipid biomarkers for Chronic Glomerulonephritis by using high performance liquid chromatography mass spectrometry
    Journal of Chromatography B, 2007
    Co-Authors: Chang Wang, Sumin Zhao, Xin Lu, Guowang Xu
    Abstract:

    Plasma phospholipids metabolic profile of Chronic Glomerulonephritis was investigated using high performance liquid chromatography/mass spectrometry (LC/MS) and principal component analysis. The plasma samples of 18 patients with Chronic Glomerulonephritis, 17 patients with Chronic renal failure (CRF) without renal replacement therapy and 18 healthy persons were collected and analyzed. It was found that combination of the LC/MS technique with PCA can be successfully applied to phospholipid profile analysis. The results showed that primary Chronic Glomerulonephritis and CRF had phospholipids metabolic abnormality. Nineteen phospholipid species were identified as possible biomarkers in plasma samples of Chronic Glomerulonephritis and Chronic renal failure. Moreover, the identification of the molecular structure of the potential phospholipid markers was obtained by ESI-MS/MS experiment. It suggests that phospholipids can be used as potential biomarkers on the progress of primary Chronic Glomerulonephritis.

  • Metabolomic identification of potential phospholipid biomarkers for Chronic Glomerulonephritis by using high performance liquid chromatography–mass spectrometry
    Journal of Chromatography B, 2007
    Co-Authors: Chang Wang, Sumin Zhao, Xin Lu, Guowang Xu
    Abstract:

    Plasma phospholipids metabolic profile of Chronic Glomerulonephritis was investigated using high performance liquid chromatography/mass spectrometry (LC/MS) and principal component analysis. The plasma samples of 18 patients with Chronic Glomerulonephritis, 17 patients with Chronic renal failure (CRF) without renal replacement therapy and 18 healthy persons were collected and analyzed. It was found that combination of the LC/MS technique with PCA can be successfully applied to phospholipid profile analysis. The results showed that primary Chronic Glomerulonephritis and CRF had phospholipids metabolic abnormality. Nineteen phospholipid species were identified as possible biomarkers in plasma samples of Chronic Glomerulonephritis and Chronic renal failure. Moreover, the identification of the molecular structure of the potential phospholipid markers was obtained by ESI-MS/MS experiment. It suggests that phospholipids can be used as potential biomarkers on the progress of primary Chronic Glomerulonephritis.

Chang Wang - One of the best experts on this subject based on the ideXlab platform.

  • metabolomic identification of potential phospholipid biomarkers for Chronic Glomerulonephritis by using high performance liquid chromatography mass spectrometry
    Journal of Chromatography B, 2007
    Co-Authors: Chang Wang, Sumin Zhao, Xin Lu, Guowang Xu
    Abstract:

    Plasma phospholipids metabolic profile of Chronic Glomerulonephritis was investigated using high performance liquid chromatography/mass spectrometry (LC/MS) and principal component analysis. The plasma samples of 18 patients with Chronic Glomerulonephritis, 17 patients with Chronic renal failure (CRF) without renal replacement therapy and 18 healthy persons were collected and analyzed. It was found that combination of the LC/MS technique with PCA can be successfully applied to phospholipid profile analysis. The results showed that primary Chronic Glomerulonephritis and CRF had phospholipids metabolic abnormality. Nineteen phospholipid species were identified as possible biomarkers in plasma samples of Chronic Glomerulonephritis and Chronic renal failure. Moreover, the identification of the molecular structure of the potential phospholipid markers was obtained by ESI-MS/MS experiment. It suggests that phospholipids can be used as potential biomarkers on the progress of primary Chronic Glomerulonephritis.

  • Metabolomic identification of potential phospholipid biomarkers for Chronic Glomerulonephritis by using high performance liquid chromatography–mass spectrometry
    Journal of Chromatography B, 2007
    Co-Authors: Chang Wang, Sumin Zhao, Xin Lu, Guowang Xu
    Abstract:

    Plasma phospholipids metabolic profile of Chronic Glomerulonephritis was investigated using high performance liquid chromatography/mass spectrometry (LC/MS) and principal component analysis. The plasma samples of 18 patients with Chronic Glomerulonephritis, 17 patients with Chronic renal failure (CRF) without renal replacement therapy and 18 healthy persons were collected and analyzed. It was found that combination of the LC/MS technique with PCA can be successfully applied to phospholipid profile analysis. The results showed that primary Chronic Glomerulonephritis and CRF had phospholipids metabolic abnormality. Nineteen phospholipid species were identified as possible biomarkers in plasma samples of Chronic Glomerulonephritis and Chronic renal failure. Moreover, the identification of the molecular structure of the potential phospholipid markers was obtained by ESI-MS/MS experiment. It suggests that phospholipids can be used as potential biomarkers on the progress of primary Chronic Glomerulonephritis.

Xin Lu - One of the best experts on this subject based on the ideXlab platform.

  • metabolomic identification of potential phospholipid biomarkers for Chronic Glomerulonephritis by using high performance liquid chromatography mass spectrometry
    Journal of Chromatography B, 2007
    Co-Authors: Chang Wang, Sumin Zhao, Xin Lu, Guowang Xu
    Abstract:

    Plasma phospholipids metabolic profile of Chronic Glomerulonephritis was investigated using high performance liquid chromatography/mass spectrometry (LC/MS) and principal component analysis. The plasma samples of 18 patients with Chronic Glomerulonephritis, 17 patients with Chronic renal failure (CRF) without renal replacement therapy and 18 healthy persons were collected and analyzed. It was found that combination of the LC/MS technique with PCA can be successfully applied to phospholipid profile analysis. The results showed that primary Chronic Glomerulonephritis and CRF had phospholipids metabolic abnormality. Nineteen phospholipid species were identified as possible biomarkers in plasma samples of Chronic Glomerulonephritis and Chronic renal failure. Moreover, the identification of the molecular structure of the potential phospholipid markers was obtained by ESI-MS/MS experiment. It suggests that phospholipids can be used as potential biomarkers on the progress of primary Chronic Glomerulonephritis.

  • Metabolomic identification of potential phospholipid biomarkers for Chronic Glomerulonephritis by using high performance liquid chromatography–mass spectrometry
    Journal of Chromatography B, 2007
    Co-Authors: Chang Wang, Sumin Zhao, Xin Lu, Guowang Xu
    Abstract:

    Plasma phospholipids metabolic profile of Chronic Glomerulonephritis was investigated using high performance liquid chromatography/mass spectrometry (LC/MS) and principal component analysis. The plasma samples of 18 patients with Chronic Glomerulonephritis, 17 patients with Chronic renal failure (CRF) without renal replacement therapy and 18 healthy persons were collected and analyzed. It was found that combination of the LC/MS technique with PCA can be successfully applied to phospholipid profile analysis. The results showed that primary Chronic Glomerulonephritis and CRF had phospholipids metabolic abnormality. Nineteen phospholipid species were identified as possible biomarkers in plasma samples of Chronic Glomerulonephritis and Chronic renal failure. Moreover, the identification of the molecular structure of the potential phospholipid markers was obtained by ESI-MS/MS experiment. It suggests that phospholipids can be used as potential biomarkers on the progress of primary Chronic Glomerulonephritis.

Sumin Zhao - One of the best experts on this subject based on the ideXlab platform.

  • metabolomic identification of potential phospholipid biomarkers for Chronic Glomerulonephritis by using high performance liquid chromatography mass spectrometry
    Journal of Chromatography B, 2007
    Co-Authors: Chang Wang, Sumin Zhao, Xin Lu, Guowang Xu
    Abstract:

    Plasma phospholipids metabolic profile of Chronic Glomerulonephritis was investigated using high performance liquid chromatography/mass spectrometry (LC/MS) and principal component analysis. The plasma samples of 18 patients with Chronic Glomerulonephritis, 17 patients with Chronic renal failure (CRF) without renal replacement therapy and 18 healthy persons were collected and analyzed. It was found that combination of the LC/MS technique with PCA can be successfully applied to phospholipid profile analysis. The results showed that primary Chronic Glomerulonephritis and CRF had phospholipids metabolic abnormality. Nineteen phospholipid species were identified as possible biomarkers in plasma samples of Chronic Glomerulonephritis and Chronic renal failure. Moreover, the identification of the molecular structure of the potential phospholipid markers was obtained by ESI-MS/MS experiment. It suggests that phospholipids can be used as potential biomarkers on the progress of primary Chronic Glomerulonephritis.

  • Metabolomic identification of potential phospholipid biomarkers for Chronic Glomerulonephritis by using high performance liquid chromatography–mass spectrometry
    Journal of Chromatography B, 2007
    Co-Authors: Chang Wang, Sumin Zhao, Xin Lu, Guowang Xu
    Abstract:

    Plasma phospholipids metabolic profile of Chronic Glomerulonephritis was investigated using high performance liquid chromatography/mass spectrometry (LC/MS) and principal component analysis. The plasma samples of 18 patients with Chronic Glomerulonephritis, 17 patients with Chronic renal failure (CRF) without renal replacement therapy and 18 healthy persons were collected and analyzed. It was found that combination of the LC/MS technique with PCA can be successfully applied to phospholipid profile analysis. The results showed that primary Chronic Glomerulonephritis and CRF had phospholipids metabolic abnormality. Nineteen phospholipid species were identified as possible biomarkers in plasma samples of Chronic Glomerulonephritis and Chronic renal failure. Moreover, the identification of the molecular structure of the potential phospholipid markers was obtained by ESI-MS/MS experiment. It suggests that phospholipids can be used as potential biomarkers on the progress of primary Chronic Glomerulonephritis.

Hiroaki Matsuoka - One of the best experts on this subject based on the ideXlab platform.

  • Efonidipine reduces proteinuria and plasma aldosterone in patients with Chronic Glomerulonephritis.
    Hypertension Research, 2007
    Co-Authors: Toshihiko Ishimitsu, Tomoko Kameda, Akira Akashiba, Toshiaki Takahashi, Satoshi Ohta, Masayoshi Yoshii, Junichi Minami, Atsushi Numabe, Hiroaki Matsuoka
    Abstract:

    Efonidipine Reduces Proteinuria and Plasma Aldosterone in Patients with Chronic Glomerulonephritis

  • efonidipine reduces proteinuria and plasma aldosterone in patients with Chronic Glomerulonephritis
    Hypertension Research, 2007
    Co-Authors: Toshihiko Ishimitsu, Tomoko Kameda, Akira Akashiba, Toshiaki Takahashi, Satoshi Ohta, Masayoshi Yoshii, Junichi Minami, Atsushi Numabe, Hiroaki Matsuoka
    Abstract:

    Efonidipine, a dihydropirydine calcium channel blocker, has been shown to dilate the efferent glomerular arterioles as effectively as the afferent arterioles. The present study compared the Chronic effects of efonidipine and amlodipine on proteinuria in patients with Chronic Glomerulonephritis. The study subjects were 21 Chronic Glomerulonephritis patients presenting with spot proteinuria greater than 30 mg/dL and serum creatinine concentrations of ≤1.3 mg/dL in men or ≤1.1 mg/dL in women. All patients were receiving antihypertensive medication or had a blood pressure ≥130/85 mmHg. Efonidipine 20–60 mg twice daily and amlodipine 2.5–7.5 mg once daily were given for 4 months each in a random crossover manner. In both periods, calcium channel blockers were titrated when the BP exceeded 130/85 mmHg. Blood sampling and urinalysis were performed at the end of each treatment period. The average blood pressure was comparable between the efonidipine and the amlodipine periods (133±10/86±5 vs. 132±8/86±5 mmHg). Urinary protein excretion was significantly less in the efonidipine period than in the amlodipine period (1.7±1.5 vs. 2.0±1.6 g/g creatinine, p=0.04). Serum albumin was significantly higher in the efonidipine period than the amlodipine period (4.0±0.5 vs. 3.8±0.5 mEq/L, p=0.03). Glomerular filtration rate was not significantly different between the two periods. Plasma aldosterone was lower in the efonidipine period than in the amlodipine period (52±46 vs. 72±48 pg/mL, p=0.009). It may be concluded that efonidipine results in a greater reduction of plasma aldosterone and proteinuria than amlodipine, and that these effects occur by a mechanism independent of blood pressure reduction. A further large-scale clinical trial will be needed in order to apply the findings of this study to the treatment of patients with renal disease.